A new study indicates that a specific psychedelic compound may effectively prevent chemotherapy-induced nerve damage in preclinical cancer models.
Researchers found that the treatment significantly reduced symptoms of neuropathy, a common and debilitating side effect of standard cancer therapies.
While promising, the findings require further clinical trials to determine safety and efficacy for human patients undergoing long-term chemotherapy.